BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM

Launched by BIOSENSORS EUROPE SA · Aug 15, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients treated with the BioMatrix AlphaTM stent per clinical indication and physician's choice;
• • Patients who agree to comply with the follow up requirements;
• • Patients with a life expectancy of \> 1 year at time of consent;
• • Patients eligible to receive dual anti platelet therapy (DAPT) according to guidelines;
• • Hemodynamically stable patients.
• Exclusion Criteria:
• • Inability to provide informed consent;
• • Currently participating in another trial before reaching primary endpoint;
• • Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless dual antiplatelet therapy is maintained throughout the perisurgical period;
• • Patient has received an additional stent different from a BioMatrix AlphaTM stent during the index procedure.